Medpacto, Vactosertib designated as ‘orphan drug’ by FDA in osteosarcoma

Medpacto, Vactosertib designated as ‘orphan drug’ by FDA in osteosarcoma Orphan drug designation for the second time only this year... Continuously expanding indications from common to rare cancers Medpacto (CEO Kim Seong-jin) said that the combination therapy of 'Vactosertib' for the treatment of osteosarcoma and immunotherapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). Medpacto received orphan drug designation for Vactosertib in pancreatic cancer in July. Medpacto said that it is rapidly expanding the indications from common cancer to ..........

원문링크 : Medpacto, Vactosertib designated as ‘orphan drug’ by FDA in osteosarcoma